# Study of Folfiri/Cetuximab in FcGammaRIIIa V/V Stage IV Colorectal Cancer Patients

> **NCT03874026** · PHASE2 · RECRUITING · sponsor: **National Cancer Institute, Naples** · enrollment: 34 (estimated)

## Conditions studied

- Colorectal Cancer
- ADCC

## Interventions

- **DRUG:** Folfiri/Cetuximab

## Key facts

- **NCT ID:** NCT03874026
- **Lead sponsor:** National Cancer Institute, Naples
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2019-09-05
- **Primary completion:** 2023-05-19
- **Final completion:** 2025-09
- **Target enrollment:** 34 (ESTIMATED)
- **Last updated:** 2024-11-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03874026

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03874026, "Study of Folfiri/Cetuximab in FcGammaRIIIa V/V Stage IV Colorectal Cancer Patients". Retrieved via AI Analytics 2026-07-04 from https://api.ai-analytics.org/clinical/NCT03874026. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*